Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

2020

Abstract Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising effica...

Keywords:

after treatment
Myeloid leukemia
Hypomethylating agent
older patients
Medicine
Internal medicine
Oncology
Azacitidine
Venetoclax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

352

Citations